Inhibition of chemotherapy resistant breast cancer stem cells by a ROR1 specific antibody.

ABSTRACT: Breast cancers enduring treatment with chemotherapy may be enriched for cancer stem cells or tumor-initiating cells, which have an enhanced capacity for self-renewal, tumor initiation, and/or metastasis. Breast cancer cells that express the type I tyrosine kinaselike orphan receptor ROR1 also may have such features. Here we find that the expression of ROR1 increased in breast cancer cells following treatment with chemotherapy, which also enhanced expression of genes induced by the activation of Rho-GTPases, Hippo-YAP/TAZ, or B lymphoma Mo-MLV insertion region 1 homolog (BMI1). Expression of ROR1 also enhanced the capacity of breast cancer cells to invade Matrigel, form spheroids, engraft in Rag2^-/-[Formula: see text] mice, or survive treatment with paclitaxel. Treatment of mice

SUBMITTER: Zhang S 

PROVIDER: S-EPMC6347692 | biostudies-literature | 2019 Jan

REPOSITORIES: biostudies-literature